Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

The immense majority of genes are alternatively spliced and there are many isoforms
specifically associated with cancer progression and metastasis. The splicing pattern of …

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …

The abundance of tumour‐infiltrating T‐cells has been associated with microsatellite
instability (MSI) and a favourable prognosis in colorectal cancer. However, numerous …

Purpose We undertook this analysis of KRAS mutation in four trials of adjuvant
chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles of …

Abnormally activated RAS proteins are the main oncogenic driver that governs the
functioning of major signaling pathways involved in the initiation and development of human …

Methods A search algorithm (Figure 1) based on a combination of the terms ''metastatic
colorectal cancer''AND “therapy” OR “treatment” AND “RAS” OR “KRAS” OR “NRAS” AND …

How do Ras isoforms attain oncogenic specificity at the membrane? Oncogenic KRas,
HRas, and NRas (K-Ras, H-Ras, and N-Ras) differentially populate distinct cancers. How …

The three mammalian RAS genes (HRAS, NRAS and KRAS) encode four proteins that play
central roles in cancer biology. Among them, KRAS is mutated more frequently in human …

Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent
developments in gene sequencing and molecular diagnostics have led to high expectations …